在心脏病中减轻阿尔多的新方法
Felix Götzinger1,2, Michael Kunz1,2, Lucas Lauder1,2
1Department of Internal Medicine III-Cardiology, Angiology and Intensive Care Medicine, Homburg University Hospital, Saarland University, Kirrberger Str. 100, Homburg 66424, Germany.
European heart journal. Cardiovascular pharmacotherapy
|July 10, 2024
概括
新的非类固醇矿物质皮质类受体抗剂 (MRA) 和阿尔多合成酶抑制剂为心血管和脏疾病提供了改进的治疗选择,克服了较旧的类固醇MRA的副作用.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类固醇矿物质皮质体受体对抗剂 (MRA) 建议用于心力衰竭,其喷射分数减少,但具有有限的选择性,导致不良反应和低持久性.
- 这些类固醇MRA也在慢性病和耐性高血压中显示出好处,但可以诱导高胆血症.
研究的目的:
- 审查和批判性地讨论针对针对心力衰竭,高血压和慢性病中的阿尔多素途径的新药的证据.
- 突出非类固醇MRA和阿尔多氨酸合成酶抑制剂的发展,作为类固醇MRA的替代品.
主要方法:
- 随机对照试验和临床研究的文献综述.
- 对新的阿尔多激素向剂的安全性和有效性数据进行批判性讨论.
主要成果:
- 芬瑞诺在延缓糖尿病脏病和减少心力衰竭住院治疗中表现出有效性,在患有慢性脏病和糖尿病的患者中.
- 在日本,esaxerenone已被批准用于治疗高血压; baxdrostat 和 lorundostat 在降低抗性高血压患者的血压方面表现有前途.
结论:
- 非类固醇MRA和阿尔多合成酶抑制剂代表了对心脏脏疾病的有前途的治疗进展.
- 与传统的类固醇MRA相比,这些新药可能提供了更好的安全性和有效性概况,解决了管理阿尔多相关疾病的未满足需求.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:25Antihypertensive Drugs: Direct Renin Inhibitors
546
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
546
01:22Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
511
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
511
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
600
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
600
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
695
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
695